PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy

Urology

Volumn 69, Issue 3, 2007, Pages 532-535

  Marks, Leonard S ^a,b   Fradet, Yves ^c   Lim Deras, Ina ^d   Blase, Amy ^d   Mathis, Jeannette ^d   Aubin, Sheila M J ^d   Cancio, Anthony T ^a   Desaulniers, Marie ^c   Ellis, William J ^e   Rittenhouse, Harry ^d   Groskopf, Jack ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

^d Gen Probe Incorporated   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROSTATE CANCER GENE 3 PROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; GENETIC TRANSCRIPTION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE ASSAY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; URINALYSIS;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; GENE EXPRESSION; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 33947276192     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.12.014     Document Type: Article

References (15)

1. Freedland S.J., and Partin A.W. Prostate-specific antigen: update 2006. Urology 67 (2006) 458-460
2. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
3. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297-1301
4. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975-5979
5. Hessels D., Klein Gunnewiek J.M., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8-16
6. de Kok J.B., Verhaegh G.W., Roelofs R.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695-2698
7. Fradet Y., Saad F., Aprikian A., et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64 (2004) 311-316
8. Tinzl M., Marberger M., Horvath S., et al. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 46 (2004) 182-187
9. Groskopf J., Aubin S.M.J., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
10. Marks L.S., Epstein J.I., and Partin A.W. The role of prostate needle biopsy in evaluation of chemopreventive agents. Urology 57 suppl 4a (2001) 191-193
11. Giachetti C., Linnen J.M., Kolk D.P., et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 40 (2002) 2408-2419
12. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
13. Thompson I.M., Carroll P., Coley C., et al. Prostate-specific antigen (PSA) best practice policy. Oncology 14 (2000) 267-286
14. Vollmer R.T. Predictive probability of serum prostate-specific antigen for prostate cancer: an approach using Bayes rule. Am J Clin Pathol 125 (2006) 336-342
15. Roehl K.A., Antenor J.A., and Catalona W.J. Serial biopsy results in prostate cancer screening study. J Urol 167 (2002) 2435-2439